Biotech News
GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology
Supports GSK's focus of using novel technologies in areas of disease expertise to advance medicines with transformative potential
Related news
RVMDRevolution Medicines2026-08-10 10:01 EST
Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration
SNYSanofi2026-09-14 13:03 EST
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
IDYAIDEAYA Biosciences2026-08-19 10:00 EST
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
GSKGSK plc2026-09-01 07:00 EST
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
GSKGSK plc2026-09-15 14:21 EST
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
SNYSanofi2026-10-01 05:00 EST
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
KURAKura Oncology2026-09-09 11:00 EST
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
TEVATeva Pharmaceutical Industries2026-09-16 12:00 EST
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-10-06 14:00 EST
ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
GSKGSK plc2026-09-15 14:21 EST
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
GSKGSK plc2026-09-13 19:30 EST
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
GSKGSK plc2026-09-13 08:00 EST
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
GSKGSK plc2026-09-10 07:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
Stock data
- Close
- 46.60 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States